Key result
The 0- to 90-day interval after stopping clopidogrel was associated with a higher risk of death or MI compared with the 91- to 360-day interval.
Why the study?
Does stopping clopidogrel increase the risk of all-cause mortality or acute MI in the first 90 days after cessation in post-ACS patients?
Cohort (n=2,017)
Does stopping clopidogrel increase the risk of all-cause mortality or acute MI in the first 90 days after cessation in post-ACS patients?
Stopping clopidogrel in post-ACS patients is associated with a transiently increased risk of death or MI in the first 90 days after cessation, suggesting possible rebound platelet hyper-reactivity.
Answers are grounded in this paper and cite their sources.
Does not yet support changing clopidogrel discontinuation in post-ACS patients; leaves open rebound hypothesis for randomized confirmation.
BACKGROUND: A prior study from the Veterans Health Administration found a clustering of cardiovascular events after clopidogrel cessation. We sought to confirm and expand these findings. METHODS AND RESULTS: This was a retrospective cohort study of 2017 patients with acute coronary syndrome discharged on clopidogrel from an integrated health care delivery system. Rates of all-cause mortality or acute myocardial infarction (MI) within 1 year after stopping clopidogrel were assessed among patients who did not have an event before stopping clopidogrel. Death/MI occurred in 4.3% (n=71) of patients. The rates of death/MI were 3.07, 1.62, 0.70, and 0.95 per 10 000 patient-days for the time intervals of 0 to 90, 91 to 180, 181 to 270, and 271 to 360 days after stopping clopidogrel. In multivariable analysis, the 0- to 90-day interval after stopping clopidogrel was associated with higher risk of death/MI (incidence rate ratio, 2.74; 95% confidence interval, 1.69 to 4.44) compared with 91- to 360-day interval. There was a similar trend of increased events after stopping clopidogrel for various subgroups (women versus men, medical therapy versus percutaneous coronary intervention, stent type, and > or =6 months or <6 months of clopidogrel treatment). Among patients taking clopidogrel but stopping ACE inhibitor medications, the event rates were similar in the 0- to 90-day versus the 91- to 360-day interval (2.67 versus 2.91 per 10 000 patient-days; P=0.91). CONCLUSIONS: We observed a clustering of adverse events in the 0 to 90 days after stopping clopidogrel. This clustering of events was not present among patients stopping ACE inhibitors. These findings are consistent with a possible rebound platelet hyper-reactivity after stopping clopidogrel and additional platelet studies are needed to confirm this effect.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2010) conducted a cohort in acute coronary syndrome (n=2,017). 0- to 90-day interval after stopping clopidogrel vs. 91- to 360-day interval after stopping clopidogrel was evaluated on all-cause mortality or acute myocardial infarction (MI) (IRR 2.74, 95% CI 1.69-4.44). The 0- to 90-day interval after stopping clopidogrel was associated with a higher risk of death or MI compared with the 91- to 360-day interval.
Synapse has enriched 10 related papers. Consider them for comparative context: